Stage 4 Cancer Survival Rates: By Age, Type & Treatment (2025 Data)

Stage 4 cancer survival rates vary dramatically by the type of cancer, the patient’s age, and the treatments available. While stage 4 always carries the most serious prognosis, it is not universally a matter of months. UK data from the Office for National Statistics and Cancer Research UK – Lung cancer survival by stage show that some cancers, such as prostate cancer, have a five‑year survival rate near 50%, while others, such as lung cancer, remain below 10%. Understanding these numbers helps patients and families put statistics into perspective.

A stage 4 diagnosis means the cancer has spread beyond its original organ to distant tissues. It is also referred to as advanced or metastatic cancer. The pattern of spread—whether to nearby lymph nodes, bones, lungs, or the liver—can change the outlook even for the same cancer type. Modern treatments, including immunotherapy and targeted therapy, have extended survival for many patients, but the variation remains wide.

This article provides a fact‑based overview of stage 4 cancer survival rates, with a focus on UK statistics, age‑related differences, and outcomes for specific organs. The data come from official sources such as the NHS, Cancer Research UK, and the American Cancer Society. No statistic can predict an individual’s future, but knowing the range can help patients ask the right questions.

What is the life expectancy for stage 4 cancer with treatment?

• Stage 4 is not a single disease; survival rates differ drastically by primary cancer site.
• With modern treatments, some patients live for years, but statistics reflect populations, not individuals.
• Age, overall health, genetic markers, and treatment response are more prognostic than the stage alone.
• UK survival data is publicly available but often not integrated into a single resource for all cancer types.
• Many top SERP results focus on one cancer type, leaving patients without a comparative view.

How do stage 4 cancer survival rates vary by age?

Age is an important predictor, though it is not the only factor. Younger patients often tolerate intensive treatment better, have fewer competing illnesses, and are more likely to receive newer therapies such as immunotherapy or targeted agents. Across multiple cancers, survival rates tend to decline with age.

Data from a lung cancer centre (not UK registry) illustrates the trend for stage 4 lung cancer: patients under 50 had a 11% survival rate, those aged 50–64 had 7%, and those 65 and older had 4.7%. Similar patterns appear in other solid tumours. However, age‑specific survival is highly cancer‑specific. A younger patient with metastatic testicular cancer or some lymphomas can achieve long‑term remission, whereas an older patient with the same diagnosis may have a different outlook.

What are the stage 4 cancer survival rates for different organs (liver, stomach, bone, ovarian, bowel)?

Stage 4 liver cancer survival rate

Liver cancer overall has a 13.4% five‑year survival in the UK (Nuffield Trust). Stage 4 liver cancer is almost always unresectable, and prognosis depends heavily on underlying liver function and whether the patient is eligible for treatments such as transarterial chemoembolisation, targeted therapy, or immunotherapy.

Stage 4 stomach cancer survival rate

UK‑specific stage 4 stomach cancer survival figures are not widely published in the sources reviewed. Generally, stomach cancer diagnosed at stage 4 has a poor prognosis, with five‑year survival below 10%. Treatment may include chemotherapy, targeted therapy for HER2‑positive cases, and palliative measures.

Stage 4 bone cancer survival rate

Bone cancer (primary) is rare, and stage‑specific UK data are limited. For primary bone sarcomas such as osteosarcoma, stage 4 (metastatic) five‑year survival is estimated at around 15–30% in some international series, but this varies widely by tumour type and response to chemotherapy.

Stage 4 ovarian cancer survival rate

Ovarian cancer often presents at a late stage. The ONS notes that its stage‑specific survival pattern is different from most other cancers—the drop at stage 4 is less steep than for lung or pancreatic cancer. Stage 4 ovarian cancer has a five‑year survival of approximately 15–25% according to some UK estimates, but this can be improved with optimal surgical debulking and platinum‑based chemotherapy.

Stage 4 bowel cancer survival rate

Stage 4 colorectal (bowel) cancer has a five‑year survival of about 15% in UK estimates. Modern approaches—including surgery for isolated liver or lung metastases, plus systemic therapy—can extend survival well beyond historical averages. Targeted therapies such as anti‑EGFR agents benefit patients with specific genetic profiles.

What are the stage 4 cancer survival rates in the UK?

The UK Office for National Statistics – Cancer survival by stage in England provides the most comprehensive official data on cancer survival by stage. For most cancers, stage 4 survival is always the worst, but the gap between early and late stages varies. The ONS’s experimental stage‑at‑diagnosis bulletin highlights that one‑year survival for stage 4 ranges from 15% for men with lung cancer to 83% for men with prostate cancer.

Cancer Research UK reports that around 50% of men with stage 4 prostate cancer stage 4 survival rate reach five years. At the other end, lung cancer stage 4 survival rate is about 5% at five years. The Nuffield Trust data show that overall UK five‑year survival for colon cancer reached 60% in 2010‑2014, but that figure includes all stages; stage 4 is far lower. Pancreatic cancer remains the poorest, with 8.3% five‑year survival overall and 43% of cases diagnosed at stage 4.

These numbers are not intended to discourage. They provide a realistic baseline against which advances in treatment can be measured. Patients should discuss their own situation with their clinical team, who can factor in tumour biology, fitness, and the latest therapies.

How have stage 4 cancer survival rates improved over time?

1. 2000s: Introduction of targeted therapies (e.g., Herceptin for HER2+ breast cancer) improves stage 4 outcomes.
2. 2010s: Immune checkpoint inhibitors (e.g., pembrolizumab) transform prognosis for melanoma, lung, and other cancers.
3. 2020s: CAR‑T cell therapy and combination regimens extend survival for multiple stage 4 cancers.
4. Ongoing: Precision medicine and liquid biopsies enable earlier, more personalised treatment.

What is certain and what remains uncertain about stage 4 cancer survival?

Why do survival rates differ so much by organ, age, and geography?

Survival differences start with the biology of each cancer. Tumours that grow in organs with rich blood supply (like the liver) or that are often detected late (pancreas, ovary) have poorer outcomes. The location also affects whether surgery is possible and which drugs work. Age effects are partly due to physiology: younger patients have better performance status, fewer comorbidities, and are more likely to receive aggressive therapy. Geographic variation reflects access to care, clinical trial availability, and screening protocols. UK statistics differ from US statistics because of differences in population health, treatment guidelines, and data collection methods.

Treatment evolution itself creates a moving target. Comparing older statistics to today may be misleading because therapies have improved so rapidly. For instance, stage 4 melanoma survival before 2010 was measured in months; today, with immunotherapy, five‑year survival can exceed 50%.

What do authoritative sources say about stage 4 cancer survival?

“Around 5 out of 100 people (around 5%) with stage 4 lung cancer will survive for 5 years or more.” – Cancer Research UK

“The range in 5‑year age‑standardised net survival by stage ranges from 3.5% (stage 4 lung cancer for males) to 101.1% (stage 1 melanoma for females).” – NHS England

“The 5‑year relative survival rate for Stage 4 breast cancer in women is 33%.” – American Cancer Society (via National Breast Cancer Foundation)

These figures come from Cancer Research UK, NHS England, National Breast Cancer Foundation, National Cancer Institute, and PubMed – Search for stage‑specific survival studies.

Summary: what should patients take away from stage 4 survival statistics?

Stage 4 cancer survival rates are population averages, not personal predictions. They show the range of outcomes—from a few months to many years—that modern medicine can achieve. Patients are encouraged to discuss their own prognosis with their oncologist, who can consider the cancer’s biology, the patient’s age and fitness, and the most up‑to‑date treatment options.

Frequently asked questions